In early March, the Cambridge, Mass.-based drugmaker said a 48-week study involving 664 ALS patients found the drug was safe and well-tolerated, but the clinical trial did not confirm overall efficacy. The FDA approved the therapy in September 2022, and Amylyx is working with officials in the U.S. and Canada to voluntarily discontinue the drug.
After discussing the results with advocacy organizations, patients, caregivers and global experts, Amylyx said patients who wish to stay on the treatment can do so for free after consulting with their physicians.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.